Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Recruiting

Phase 1

HWK-007Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Sponsor:

Whitehawk Therapeutics, Inc.

Code:

NCT07444814

Conditions

Endometrial Cancer

Ovarian Cancer

Ovarian Cancer Metastatic

Ovarian Cancer Metastatic Recurrent

Non-squamous EGFR Wt NSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

HWK-007

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-10. This information was provided to ClinicalTrials.gov by Whitehawk Therapeutics, Inc. on 2026-03-03.